mk-0616
merck
['cardio']
late breaking clinical trial: efficacy and safety of the oral pcsk9 inhibitor, mk-0616, a macrocyclic peptide in the treatment of hypercholesterolemia: a phase 2b randomized placebo controlled clinical trial #cardionerds 
MS4 @StGeorgesU | Aspiring Internist/ Interventional Cardiologist🫀 | Dog Mom 🐶 | @Cardionerds Academy Intern | @AMWAStudent Global Health Fellow | ❤️Arugula